CRESTOR reduces major cardiovascular events in women by 46%
October 02, 2017
Initial results from JUPITER, originally presented in November 2008 at the American Heart Association's Annual Scientific Sessions and published by the New England Journal of Medicine, showed rosuvastatin 20mg significantly reduced major cardiovascular (CV) events (combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by 44% compared to placebo (p(less than)0.00001).(4) These results also showed that for patients in the trial taking rosuvastatin 20mg the combined risk of heart attack, stroke or CV death was reduced by nearly half (47%, p(less than)0.00001).(5)
There were 6,801 female participants (38.2% of the entire study population of 17,802) randomized to receive either rosuvastatin 20mg once daily or placebo.
CRESTOR is indicated as an adjunct to diet in the treatment of high cholesterol. The 40mg dose is the highest approved dose of CRESTOR. CRESTOR is not indicated for atherosclerosis or for the reduction of mortality and morbidity. CRESTOR should be used according to the prescribing information, which contains recommendations for initiating and titrating therapy according to the individual patient profile. In Canada, the recommended starting dose of CRESTOR in most patients is 10 mg orally once daily.
With over 160 million prescriptions written worldwide, CRESTOR has been prescribed to more than 15 million patients and has a safety profile in line with that of other marketed statins.
Source: ASTRAZENECA CANADA INC.